Trial · NCT01333592
Adverse events40
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 40
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bronchitis | Infections and infestations | KAD-1229 / DPP-4 Inhibitors | 2 | 67 | |
| other | Bronchitis | Infections and infestations | KAD-1229 / Biguanides | 8 | 69 | |
| other | Nasopharyngitis | Infections and infestations | KAD-1229 / DPP-4 Inhibitors | 17 | 67 | |
| other | Nasopharyngitis | Infections and infestations | KAD-1229 / Biguanides | 30 | 69 | |
| other | Pharyngitis | Infections and infestations | KAD-1229 / DPP-4 Inhibitors | 6 | 67 | |
| other | Pharyngitis | Infections and infestations | KAD-1229 / Biguanides | 2 | 69 | |
| other | Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | KAD-1229 / DPP-4 Inhibitors | 5 | 67 | |
| other | Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | KAD-1229 / Biguanides | 5 | 69 | |
| other | Dental caries | Gastrointestinal disorders | KAD-1229 / DPP-4 Inhibitors | 0 | 67 | |
| other | Dental caries | Gastrointestinal disorders | KAD-1229 / Biguanides | 4 | 69 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | KAD-1229 / DPP-4 Inhibitors | 4 | 67 | |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | KAD-1229 / Biguanides | 1 | 69 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | KAD-1229 / DPP-4 Inhibitors | 4 | 67 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | KAD-1229 / Biguanides | 1 | 69 | |
| other | Alanine aminotransferase increase | Investigations | KAD-1229 / DPP-4 Inhibitors | 0 | 67 | |
| other | Alanine aminotransferase increase | Investigations | KAD-1229 / Biguanides | 5 | 69 | |
| other | γ-glutamyltransferase increase | Investigations | KAD-1229 / DPP-4 Inhibitors | 4 | 67 | |
| other | γ-glutamyltransferase increase | Investigations | KAD-1229 / Biguanides | 7 | 69 | |
| other | Blood urine present | Investigations | KAD-1229 / DPP-4 Inhibitors | 0 | 67 | |
| other | Blood urine present | Investigations | KAD-1229 / Biguanides | 4 | 69 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01333592/events